An2 Therapeutics Stock Performance
| ANTX Stock | USD 1.46 0.05 3.55% |
AN2 Therapeutics has a performance score of 3 on a scale of 0 to 100. The firm owns a Beta (Systematic Risk) of 0.6, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, AN2 Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding AN2 Therapeutics is expected to be smaller as well. AN2 Therapeutics today owns a risk of 2.81%. Please confirm AN2 Therapeutics value at risk, and the relationship between the standard deviation and kurtosis , to decide if AN2 Therapeutics will be following its current price history.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in AN2 Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, AN2 Therapeutics may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
1 | Grammy Winner Ann Nesby Teams with R.L., Lead Singer of Platinum-Selling Group Next, for Soulful Love Anthem My Man | 01/24/2025 |
2 | Fay Raises 50M Series B at a 500M Valuation to Revolutionize How We Think and Feel About Food | 02/05/2025 |
3 | U.S. Anthem Booed Before Americans 4 Nations Face-Off Game In Montreal | 02/14/2025 |
4 | Pelvic Rehabilitation Medicine in Los Angeles Now In-Network with Anthem | 02/18/2025 |
5 | Impossible Its Possible Became Their Anthem | 02/21/2025 |
6 | Acquisition by Stephen Prior of 56000 shares of AN2 Therapeutics at 1.13 subject to Rule 16b-3 | 02/26/2025 |
7 | Teva Releases New Spring 2025 Sandal Collection and Anthem | 03/04/2025 |
8 | Novel Romance Releases Bond-Inspired Anthem and Video Golden Nights | 03/06/2025 |
9 | Theo Evan Unveils Shh Cyprus Enigmatic Dance Anthem for Eurovision 2025 | 03/12/2025 |
10 | National Anthem Announced, Nitish Kumar Walks Off Stage At Sports Event | 03/20/2025 |
| Begin Period Cash Flow | 27.2 M |
AN2 |
AN2 Therapeutics Relative Risk vs. Return Landscape
If you would invest 140.00 in AN2 Therapeutics on December 21, 2024 and sell it today you would earn a total of 6.00 from holding AN2 Therapeutics or generate 4.29% return on investment over 90 days. AN2 Therapeutics is currently generating 0.1083% in daily expected returns and assumes 2.8053% risk (volatility on return distribution) over the 90 days horizon. In different words, 25% of stocks are less volatile than AN2, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
AN2 Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AN2 Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AN2 Therapeutics, and traders can use it to determine the average amount a AN2 Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0386
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | ANTX | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.81 actual daily | 25 75% of assets are more volatile |
Expected Return
| 0.11 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average AN2 Therapeutics is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AN2 Therapeutics by adding it to a well-diversified portfolio.
AN2 Therapeutics Fundamentals Growth
AN2 Stock prices reflect investors' perceptions of the future prospects and financial health of AN2 Therapeutics, and AN2 Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AN2 Stock performance.
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.32 | ||||
| Current Valuation | (51.62 M) | ||||
| Shares Outstanding | 29.88 M | ||||
| Price To Earning | 3.96 X | ||||
| Price To Book | 0.50 X | ||||
| EBITDA | 4.9 M | ||||
| Net Income | (64.73 M) | ||||
| Cash And Equivalents | 113.39 M | ||||
| Cash Per Share | 5.84 X | ||||
| Total Debt | 14.04 M | ||||
| Current Ratio | 28.17 X | ||||
| Book Value Per Share | 2.94 X | ||||
| Cash Flow From Operations | (53.29 M) | ||||
| Earnings Per Share | (1.99) X | ||||
| Market Capitalization | 43.62 M | ||||
| Total Asset | 138.74 M | ||||
| Retained Earnings | (154.46 M) | ||||
| Working Capital | 96.46 M | ||||
About AN2 Therapeutics Performance
Evaluating AN2 Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if AN2 Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if AN2 Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.50) | (0.53) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | (0.47) | (0.44) |
Things to note about AN2 Therapeutics performance evaluation
Checking the ongoing alerts about AN2 Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AN2 Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AN2 Therapeutics may become a speculative penny stock | |
| AN2 Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (64.73 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| AN2 Therapeutics currently holds about 113.39 M in cash with (53.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.84, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 23.0% of the company shares are held by company insiders | |
| Latest headline from ndtv.com: National Anthem Announced, Nitish Kumar Walks Off Stage At Sports Event |
- Analyzing AN2 Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AN2 Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining AN2 Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AN2 Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of AN2 Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AN2 Therapeutics' stock. These opinions can provide insight into AN2 Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for AN2 Stock Analysis
When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.